// App-Quantinova.ai

: Characterization of Terminal Erythroid Differentiation (TED) and Its Prognosis Impact Inpatients with Myelodysplastic Syndrome (MDS)

Researchers

Presenter

  • Marc Bosch Schips

Principal Investigators

  • Julia Montoro

  • Félix López Cadenas

  • Alba Mesa

  • Víctor Navarro Garcés

  • Ana Perez

  • Laura Gallur

  • Silvia Saumell

  • Mayda Navarrete

  • Margarita Ortega

  • Barbara Tazon

  • Antonieta Molero

  • Olga Salamero

  • Sandra Novoa Jáuregui

  • Sofia Laura Muzio

  • Francesc Bosch

  • David Valcarcel

Medical Centers

  • Department of Hematology. Vall d'Hebron Institute of Oncology (VHIO), University Hospital Vall d'Hebron., Barcelona, Spain, Barcelona, Spain

  • Grupo Español de Síndromes Mielodisplásicos (GESMD), Valencia, Spain

  • Department of Hematology, University Hospital Vall d'Hebron, University Autonoma of Barcelona (UAB), Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Oncology Data Science (ODysSey) Group, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Barcelona, Spain

  • Department of Hematology, Vall D'Hebron Hospital Universitari, Experimental Hema, Barcelona, ESP

  • Hematology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain

  • Servei d'Hematologia, Vall d'Hebron Hospital Universitari, Experimental Hematology, Vall d'Hebron Institute of Oncology (VHIO), Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain

  • Department of Hematology. Salamanca-IBSAL university hospital, Salamanca, Spain

  • Department of Hematology, Vall D`Hebron University Hospital, Barcelona, ESP

  • Department of Hematology, University Hospital Vall d'Hebron, Experimental Hematology Unit, Vall d'Hebron Institute of Oncology (VHIO), University Autonoma of Barcelona (UAB), BARCELONA, Spain

  • Hospital Universitari Vall D'Hebron, Barcelona, Spain

  • Spanish CLL Study Group, Madrid, Spain

Locations

  • Spain

  • Venezuela

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Alpha-thalassemia myelodysplasia syndrome

  • Lymphomas

Biomarkers

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved